The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo

Journal of Immunology

Volumn 194, Issue 5, 2015, Pages 2199-2207

  Silva, Anabel ^a   Mount, Adele ^a   Krstevska, Karoline ^a   Pejoski, David ^a   Hardy, Matthew P ^a   Owczarek, Catherine ^a   Scotney, Pierre ^a   Maraskovsky, Eugene ^a   Morelli, Adriana Baz ^a  

^a CSL LIMITED   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; ISCOMATRIX VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; CHOLESTEROL; DRUG COMBINATION; IMMUNOLOGICAL ADJUVANT; ISCOMATRIX; OLIGODEOXYRIBONUCLEOTIDE; PHOSPHOLIPID; SAPONIN; TLR3 PROTEIN, MOUSE; TLR9 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CPG ISLAND; DRUG EFFICACY; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CYTOTOXICITY; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; MALE; MELANOMA, EXPERIMENTAL; MORTALITY; PANCREATIC NEOPLASMS; PROCEDURES; PROSTATIC NEOPLASMS; SKIN NEOPLASMS; SURVIVAL; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CHOLESTEROL; CYTOTOXICITY, IMMUNOLOGIC; DRUG COMBINATIONS; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; OLIGODEOXYRIBONUCLEOTIDES; PANCREATIC NEOPLASMS; PHOSPHOLIPIDS; POLY I-C; PROSTATIC NEOPLASMS; SAPONINS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 9; TUMOR BURDEN;

EID: 84924348165     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402228     Document Type: Article

References (27)

1. Schiller, J. T., X. Castellsagué, and S. M. Garland. 2012. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30(Suppl. 5): F123-F138.
2. Venters, C., W. Graham, and W. Cassidy. 2004. Recombivax-HB: perspectives past, present and future. Expert Rev. Vaccines 3: 119-129.
3. Harzstark, A. L., and E. J. Small. 2007. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Expert Opin. Biol. Ther. 7: 1275-1280.
4. Mount, A., S. Koernig, A. Silva, D. Drane, E. Maraskovsky, and A. B. Morelli. 2013. Combination of adjuvants: the future of vaccine design. Expert Rev. Vaccines 12: 733-746.
5. + T cells enter the scene. Cell. Mol. Life Sci. 68: 3457-3467.
6. + T cell help. J. Exp. Med. 186: 65-70.
7. Drane, D., C. Gittleson, J. Boyle, and E. Maraskovsky. 2007. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev. Vaccines 6: 761-772.
8. + T cells. J. Immunol. 187: 55-63.
9. + T-cell cross-priming by a MyD88-dependent signaling pathway. Immunol. Cell Biol. 90: 540-552.
10. McKenzie, A., M. Watt, and C. Gittleson. 2010. ISCOMATRIX() vaccines: Safety in human clinical studies. Hum. Vaccin. 6: 237-246.
11. Kabelitz, D., and R. Medzhitov. 2007. Innate immunity - cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Curr. Opin. Immunol. 19: 1-3.
12. Palm, N. W., and R. Medzhitov. 2009. Pattern recognition receptors and control of adaptive immunity. Immunol. Rev. 227: 221-233.
13. + T-cell responses in melanoma patients. Eur. J. Immunol. 42: 3049-3061.
14. Hong, X., T. Dong, J. Hu, T. Yi, W. Li, Z. Zhang, S. Lin, and W. Niu. 2013. Synergistical Toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer. Int. J. Colorectal Dis. 28: 25-33.
15. Steinhagen, F., T. Kinjo, C. Bode, and D. M. Klinman. 2011. TLR-based immune adjuvants. Vaccine 29: 3341-3355.
16. Vasilakos, J. P., and M. A. Tomai. 2013. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Rev. Vaccines 12: 809-819.
17. Wilson, N. S., P. Duewell, B. Yang, Y. Li, S. Marsters, S. Koernig, E. Latz, E. Maraskovsky, A. B. Morelli, M. Schnurr, and A. Ashkenazi. 2014. Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant. J. Immunol. 192: 3259-3268.
18. + T-cell help. Eur. J. Immunol. 42: 1080-1088.
19. Johnson, S., Y. Zhan, R. M. Sutherland, A. M. Mount, S. Bedoui, J. L. Brady, E. M. Carrington, L. E. Brown, G. T. Belz, W. R. Heath, and A. M. Lew. 2009. Selected Toll-like receptor ligands and viruses promote helper-independent cytotoxic T cell priming by upregulating CD40L on dendritic cells. Immunity 30: 218-227.
20. Medzhitov, R., and C. A. Janeway, Jr. 2002. Decoding the patterns of self and nonself by the innate immune system. Science 296: 298-300.
21. Ikeda, H., L. J. Old, and R. D. Schreiber. 2002. The roles of IFN γ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13: 95-109.
22. LaCasse, C. J., N. Janikashvili, C. B. Larmonier, D. Alizadeh, N. Hanke, J. Kartchner, E. Situ, S. Centuori, M. Har-Noy, B. Bonnotte, et al. 2011. Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism. J. Immunol. 187: 6310-6317.
23. Li, P., Q. Du, Z. Cao, Z. Guo, J. Evankovich, W. Yan, Y. Chang, L. Shao, D. B. Stolz, A. Tsung, and D. A. Geller. 2012. Interferon-γ induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1). Cancer Lett. 314: 213-222.
24. Ngiow, S. F., B. von Scheidt, H. Akiba, H. Yagita, M. W. Teng, and M. J. Smyth. 2011. Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res. 71: 3540-3551.
25. Xiao, H., Y. Peng, Y. Hong, L. Huang, Z. S. Guo, D. L. Bartlett, N. Fu, D. H. Munn, A. Mellor, and Y. He. 2013. Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization. J. Immunol. 190: 5866-5873.
26. McCluskie, M. J., R. R. Weeratna, D. M. Evans, S. Makinen, D. Drane, and H. L Davis. 2013. CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-cell IFN-γ responses. Biomed. Res. Int. 2013: 636847.
27. Perret, R., S. R. Sierro, N. K. Botelho, S. Corgnac, A. Donda, and P. Romero. 2013. Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. Cancer Res. 73: 6597-6608.